Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations

Thrombosis Research

Volumn 112, Issue 3, 2003, Pages 131-135

  Kornblihtt, L I ^a   Heller, P G ^a   Correa, G ^a   Castanon M ^b   Genoud, V ^b   Vassallu, P ^a   Sarano, J ^a   Kordich, L ^b   Molinas, F C ^a  

^a INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Essential thrombocythaemia; Factor V Leiden; Homocysteine; Prothrombin G20210A; Thrombophilic defects; Thrombosis

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANAGRELIDE; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; HYDROXYUREA; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC RISK; HEREDITY; HOMOCYSTINURIA; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; SCHOOL CHILD; THROMBOCYTHEMIA; THROMBOPHILIA; THROMBOSIS;

EID: 1042287055     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.11.012     Document Type: Article

References (19)

1. Murphy S. Diagnostic criteria and prognosis in Polycythemia Vera and Essential Thrombocythemia. Semin. Hematol. 36:1999;9-13.
2. Tefferi A., Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis and management. Blood Rev. 15:2001;121-131.
3. Cortelazzo S., Viero P., Finazzi G., D'Emilio A., Rodeghiero F., Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 8:1990;556-562.
4. Watson K.V., Key N. Vascular complications of essential thrombocythemia: a link to cardiovascular risk factors. Br. J. Haematol. 83:1993;198-203.
5. Kornblihtt L.I., Vassallu P.S., Heller P., Molinas F.C. Diez años de experiencia con anagrelide en el tratamiento de la trombocitemia esencial. Medicina. 62:2002;231-236.
6. Bertina R.M., Koeleman B.P.C., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H.et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 369:1994;64-67.
7. Poort S.R., Rosendaal F.R., Reitsma P.H., Bertina R.M. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 88:1996;3698-3703.
8. Froost P., Blom H.J., Milos R., Goye Ten P., Shepard C.A., Mathews R.G. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenentetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
9. Gisslinger H., Rodeghiero F., Ruggieri M., Fard N.H.V., Mannhalter C., Papagiannopoulis M.et al. Homocysteine levels in polycythemia vera and essential thrombocythemia. Br. J. Haematol. 105:1999;551-555.
10. Amitrano L., Guardasciones M.A., Ames P.R.J., Maargaglione M., Antinolfi I., Iannaccone L.et al. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splachnic vein thrombosis and arterial disease. Am. J. Hematol. 72:2003;75-81.
11. Wieczorek I., Mac Gregor I.R., Ludlam C.A. Low proteins C and S and activation of fibrinolysis in treated in essencial thombocythemia. Am. J. Hematol. 49:1995;277-281.
12. Jensen M., Brown P., Thorsen S., Hasselbalch H. Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders. Am. J. Hematol. 69:2002;185-191.
13. Bucalossi A., Marotta G., Bigazzi C.et al. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am. J. Hematol. 52:1996;14-20.
14. Harrison C., Donohoe S., Carr P., Dave M., Mackie I., Machin S. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb. Haemost. 87:2002;802-807.
15. Afshai-Kharghan V., López J.A., Gray L.A.et al. Hemostatic gene polymorphisms and the prevalence of thrombohemorrahagic complications in polycythemia vera and essential thrombocythemia. [abstract] Blood. 98:2001;471a.
16. Ruggieri M., Gisslinger H., Tosetto A., Rintelen C., Mannhalter C., Pabinger I.et al. Factor V Leiden mutation carriership and venus thromboembolism in Polycythemia Vera and Essential Thrombocythemia. Am. J. Hematol. 71:2002;1-6.
17. Genoud V., Castañon M., Annichino-Bizzacchi J., Korin J., Kordich L. Prevalence of three prothrombotic polymorphisms: factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T in Argentina. Thromb. Res. 100:2000;127-131.
18. Bratström L., Wilcken D.E.L., Öhrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation. 98:1998;2520-2526.
19. Lane D.A., Grant P.J. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 95:2000;1517-1532.